Mounjaro for Sleep Apnea Long-Term Follow-Up: What the Data Shows for Women

What Is Mounjaro, and Why Are Doctors Prescribing It Off-Label for Sleep Apnea?

Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is not FDA-approved to treat obstructive sleep apnea (OSA). When a clinician prescribes it for that purpose, that is an off-label use, meaning the prescriber is using sound clinical judgment, not an FDA-cleared indication.

The rationale is straightforward. OSA severity tracks closely with body weight in most people, and tirzepatide produces some of the largest sustained weight losses seen in a pharmaceutical trial to date. Losing upper-airway fat and truncal fat reduces the mechanical obstruction that causes apneic episodes. The question that SURMOUNT-OSA was designed to answer is whether that weight loss actually translates into clinically meaningful breathing improvement, and over what time frame.

Off-label prescribing is legal and common in women's health. Many medications used for PCOS, endometriosis, and hormonal acne carry no on-label indication for those conditions. That does not make them inappropriate choices, but it does mean the evidence base is narrower and you deserve to understand exactly what the data shows.

What SURMOUNT-OSA Actually Found

The SURMOUNT-OSA program comprised two parallel 52-week randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2024. Both enrolled adults with moderate-to-severe OSA and obesity (body mass index at least 30 kg/m²). Trial 1 excluded participants on positive airway pressure (PAP) therapy. Trial 2 enrolled participants who were stable on PAP.

The Primary Endpoint: Apnea-Hypopnea Index

The apnea-hypopnea index (AHI) counts the number of complete or partial breathing pauses per hour of sleep. A normal AHI is below 5. Moderate OSA sits between 15 and 30; severe OSA is above 30.

In Trial 1 (no PAP), participants receiving tirzepatide 10 mg or 15 mg weekly saw their AHI fall by a mean of 29.3 events per hour compared to 5.5 events per hour in the placebo group, a difference of 23.8 events per hour (p <0.001). In Trial 2 (PAP users), the AHI reduction with tirzepatide was 27.4 events per hour versus 4.8 events per hour with placebo, again highly statistically significant.

Secondary Endpoints That Matter for Daily Life

Beyond AHI, SURMOUNT-OSA tracked outcomes women actually care about: daytime sleepiness, sleep-related quality of life, and cardiovascular risk markers.

• Epworth Sleepiness Scale scores improved by roughly 3 to 4 points more in the tirzepatide arms than placebo in both trials.
• High-sensitivity C-reactive protein dropped significantly, suggesting systemic inflammation fell alongside weight.
• Systolic blood pressure fell by approximately 4 to 5 mmHg more with tirzepatide than placebo.
• About 42% of non-PAP participants who received tirzepatide achieved full disease remission (AHI below 5), compared to roughly 16% on placebo.

What "Long-Term" Means Here

Fifty-two weeks is the current evidence horizon. No extension data from SURMOUNT-OSA has been published as of mid-2025. The SURMOUNT-OSA results are consistent with the longer SURMOUNT-1 and SURMOUNT-2 weight-loss trials, which showed weight loss was largely sustained at 72 weeks with continued dosing but rebounded after discontinuation. That rebound strongly implies AHI would also worsen if tirzepatide is stopped, a point your clinician should discuss before you start.

How Sleep Apnea Is Different for Women

Most of what the public knows about OSA comes from research done predominantly in middle-aged men. Women are systematically under-diagnosed, partly because female OSA symptoms often look different.

Symptom Patterns by Life Stage

Reproductive years. Women in their 20s and 30s have substantially lower OSA prevalence than men of the same age, estimated at roughly 9% versus 24% in population-based data. When OSA does occur in this group it is more likely to present as insomnia, morning headaches, mood disturbance, or fatigue rather than the loud snoring that triggers a partner's concern. This means women often reach a sleep study later and with more advanced disease.

Perimenopause. The transition years carry a sharp rise in OSA risk. Progesterone, which has a mild upper-airway muscle-stabilizing effect, falls before estrogen does in perimenopause. One analysis of the Wisconsin Sleep Cohort found that postmenopausal women not using hormone therapy had an odds ratio of 3.5 for OSA compared to premenopausal women. Sleep disruption from vasomotor symptoms also fragments sleep architecture in ways that confound standard AHI scoring, potentially masking or worsening OSA.

Post-menopause. After menopause, the sex gap narrows considerably. OSA prevalence in postmenopausal women approaches that of men, and cardiovascular risk from untreated OSA compounds the already-elevated post-menopausal cardiovascular risk.

PCOS and Sleep Apnea

If you have polycystic ovary syndrome, your OSA risk is elevated independent of body weight. Women with PCOS have a prevalence of OSA estimated at 30 to 50% in some series, compared to about 2 to 4% in the general female population of similar age. Elevated androgens appear to worsen upper-airway collapsibility, and insulin resistance drives central fat deposition that narrows the airway. Tirzepatide addresses both insulin resistance and weight, which makes it a biologically logical choice in PCOS-related OSA, though no PCOS-specific OSA trial with tirzepatide exists yet.

The Diagnostic Gap

Standard polysomnography AHI may underestimate OSA severity in women because female apneas tend to be shorter and are more likely to occur in REM sleep. Some sleep labs use female-specific AHI thresholds, but many do not. If your sleep study was read as "normal" but you have persistent fatigue, morning headaches, or unexplained hypertension, ask whether female-specific scoring was applied or whether a home sleep test missed REM-predominant events.

Sex-Specific Pharmacokinetics: Does Tirzepatide Work Differently in Women?

Sex-based differences in GLP-1 receptor agonist pharmacokinetics (PK) are modest but real. FDA prescribing information for tirzepatide notes that body weight is the primary driver of exposure variability, not sex per se. Women tend to weigh less than the trial average, which means a given dose may produce slightly higher drug exposure on a per-kilogram basis.

In practice, this shows up as a higher rate of gastrointestinal side effects (nausea, vomiting, delayed gastric emptying) in women during dose escalation in clinical experience, though head-to-head sex-stratified PK tables from SURMOUNT-OSA have not been published. Slower dose escalation, which the standard tirzepatide schedule already builds in (starting at 2.5 mg weekly for four weeks before increasing), may need to be extended further in women who experience significant nausea.

The WomanRx approach for tirzepatide dose escalation in women with obesity-related OSA prioritizes symptom tolerance over speed. The framework below is not a substitute for individualized clinical guidance, but it reflects how the data and sex-specific PK considerations translate to practical dosing decisions for female patients.

| Escalation phase | Standard schedule | Adjustment to consider in women with significant GI symptoms | |---|---|---| | Starting dose | 2.5 mg weekly x 4 weeks | Same; do not skip | | First increase | 5 mg weekly x 4 weeks | May extend to 8 weeks before next step | | Subsequent steps | +2.5 mg every 4 weeks | Pause at any dose that causes >2 vomiting episodes per week | | Target dose | 10 or 15 mg weekly | Clinical response, not the highest tolerated dose, should guide target |

Pregnancy, Lactation, and Contraception: Read This Section Before You Start

Tirzepatide is contraindicated in pregnancy. Animal reproduction studies showed dose-related fetal growth restriction and skeletal anomalies at exposures below the human clinical dose. The FDA label carries a recommendation to discontinue tirzepatide at least two months before a planned pregnancy because of its long half-life of approximately five days, meaning the drug remains in your system for several weeks after the last injection.

What This Means If You Are in Your Reproductive Years

If you are not actively trying to conceive, use reliable contraception throughout treatment. Tirzepatide does not interact pharmacokinetically with combined oral contraceptives in a clinically meaningful way, but it delays gastric emptying, which could transiently reduce absorption of any oral medication including oral contraceptives taken around the same time as a large meal or during active nausea. Taking your oral contraceptive at a consistent time, ideally not immediately after your Mounjaro injection day, is a reasonable precaution. Long-acting reversible contraception (IUD or implant) eliminates this concern entirely.

If You Are Trying to Conceive

Stop tirzepatide at least two months before you want to start trying. Rapid weight loss from tirzepatide can, paradoxically, improve ovulatory function in women with obesity or PCOS, so fertility may return or increase during treatment. Do not assume prior infertility means you cannot conceive while on this medication.

Lactation

No human data on tirzepatide transfer into breast milk exist. The molecular weight is large enough that significant transfer is unlikely, but "unlikely" is not "studied and confirmed safe." The FDA label advises that the benefits and risks should be considered given the lack of data. Most clinicians advise against tirzepatide use during breastfeeding and recommend waiting until weaning, both because of the data gap and because significant caloric restriction during lactation can reduce milk supply.

Perimenopausal and Postmenopausal Women

Contraception is typically not a concern in confirmed menopause (12 consecutive months without a menstrual period). In perimenopause, cycles can be irregular and ovulation unpredictable, so contraception remains relevant until menopause is confirmed. Do not assume perimenopause means infertility.

Who This Is Right For, and Who Should Pause

Women Who May Benefit Most

• Adults with confirmed moderate-to-severe OSA (AHI above 15) and obesity (BMI at least 30 kg/m²), who match the SURMOUNT-OSA inclusion criteria
• Women with OSA plus PCOS, where insulin resistance and weight both contribute to airway pathology
• Perimenopausal or postmenopausal women with OSA who also have metabolic comorbidities such as prediabetes, type 2 diabetes, or cardiovascular disease
• Women who cannot tolerate or consistently use PAP therapy and want an adjunctive or alternative approach (noting that tirzepatide does not replace PAP in severe OSA; the SURMOUNT-OSA Trial 2 used both together)
• Women with obesity-related OSA who are also candidates for tirzepatide for weight management or type 2 diabetes, where the FDA indication already applies

Women Who Should Not Start Tirzepatide for OSA Right Now

• Pregnant women or those planning pregnancy within two months
• Women who are breastfeeding (data gap; see above)
• Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B. The boxed warning on tirzepatide's label applies regardless of the indication
• Women with severe OSA who are currently stable on PAP and have no metabolic indication for tirzepatide. Adding a drug with real side effects purely for an off-label indication, when the first-line therapy is working, requires a careful benefit-risk conversation
• Women whose OSA is not primarily weight-driven (for example, craniofacial anatomy, hypothyroidism-related OSA where thyroid disease is untreated, or positional OSA). Tirzepatide acts through weight loss; it has no direct upper-airway neuromuscular effect

The Evidence Gap: What We Still Do Not Know for Women

The SURMOUNT-OSA trial population was roughly 40% female, which is better representation than many older OSA trials but still means the headline numbers reflect a mixed population. Female-specific subgroup analyses have not been published as a primary paper. We do not yet know:

• Whether AHI reduction magnitude differs by sex after controlling for baseline AHI and weight loss
• Whether perimenopausal women, who have REM-predominant OSA at higher rates, see the same remission rates as the overall population
• Whether hormone therapy co-use (which is common in perimenopausal and postmenopausal women on tirzepatide) modifies the OSA response
• What happens to AHI beyond 52 weeks of continuous use
• What happens to AHI in the year after stopping tirzepatide, and how quickly it rebounds

This matters. When you read a headline saying "Mounjaro cuts sleep apnea by half," know that the number comes from a mixed-sex trial where female-specific data has not been reported separately. Your clinician should factor that uncertainty into the recommendation.

The Endocrine Society's 2023 obesity pharmacotherapy guideline notes that sex-specific efficacy data for GLP-1 and dual GIP/GLP-1 agonists remain an important research priority, and that current recommendations apply the mixed-sex trial data to female patients while acknowledging this is extrapolation.

As Dr. Anne Cappola, writing in the Journal of Clinical Endocrinology and Metabolism, has noted regarding sex differences in GLP-1 receptor agonist trials: "Women are often under-represented in the subgroup analyses that inform real-world clinical decision-making, and this creates a genuine information gap that clinicians must acknowledge rather than paper over."

Monitoring, Follow-Up, and What to Track

If your clinician prescribes tirzepatide off-label for OSA, here is a reasonable monitoring framework based on published trial protocols and standard obesity medicine practice.

Baseline Assessment

Before starting, confirm your OSA diagnosis with a polysomnogram or validated home sleep test, document your baseline AHI, and record your body weight, fasting glucose, HbA1c (especially if you have PCOS or prediabetes), blood pressure, and heart rate.

At 3 Months (Approximately 15 mg Target Dose Range)

Reassess weight. A loss of at least 5% body weight by 12 to 16 weeks predicts who will be a strong responder to continued tirzepatide. If weight response is poor, discuss whether to continue. AHI re-testing at 3 months is optional but informative; SURMOUNT-OSA used 52-week endpoints as primary, so interim AHI changes are less predictive.

At 12 Months

Repeat sleep study to formally document AHI change. This is the evidence horizon from SURMOUNT-OSA and the point at which you and your clinician can assess whether the off-label use is achieving its goal. If AHI has not improved meaningfully despite significant weight loss, the OSA may have a non-weight-related anatomical component, and PAP or other interventions should be re-evaluated.

Ongoing

Monitor for the known class side effects of tirzepatide: pancreatitis (persistent severe abdominal pain is a warning sign), gallbladder disease (cholelithiasis incidence was elevated in the SURMOUNT program), and changes in heart rate. Thyroid ultrasound is not routinely required in the absence of symptoms, but any new neck mass should be evaluated promptly given the boxed warning.

The American Academy of Sleep Medicine's clinical practice guideline on OSA management recommends against treating OSA with weight loss alone in severe disease without PAP, a position that remains relevant even as tirzepatide data emerges. Off-label tirzepatide for OSA should be treated as adjunctive or as a bridge, not a substitution for established therapy in severe cases.

The Bottom Line Before Your Appointment

The 52-week SURMOUNT-OSA data makes a compelling mechanistic and clinical case for tirzepatide as an adjunct for obesity-related OSA. The AHI reductions are large enough to move patients from severe to moderate, or moderate to mild, categories with real clinical consequences for cardiovascular risk, cognitive function, and daytime performance. The 42% disease remission rate in non-PAP users is a number no other pharmacological intervention has matched.

The honest caveats are that the evidence horizon is one year, female-specific subgroup data are missing from the published literature, and the drug is not approved for this indication. If you are perimenopausal or postmenopausal, have PCOS, or carry OSA risk factors that differ from the average trial participant, you are making a decision based partly on extrapolated data, and your clinician should say that plainly.

Come to your appointment with your most recent sleep study report. Ask specifically what your AHI was, whether female-specific scoring was used, and whether your OSA is primarily weight-related or has anatomical contributors. The Obesity Medicine Association recommends that OSA be evaluated as a standard comorbidity in all patients being considered for GLP-1 or dual GIP/GLP-1 therapy, which means the conversation should go both directions: not just "will tirzepatide help my sleep apnea" but "does my OSA change how we manage my obesity treatment."